FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients were eligible to participate if they were aged 50 years or over, with a history of MI (1 to 3 years prior to randomisation), and had at least one of the following risk factors for atherothrombosis: age ≥65 years, diabetes mellitus requiring medication, a second prior MI, evidence of multivessel CAD or chronic non-end-stage renal dysfunction.
Croatian: Za sudjelovanje u studiji bili su podobni bolesnici u dobi od 50 ili više godina, s IM u anamnezi (1 do 3 godine prije randomizacije) te koji su imali najmanje jedan od sljedećih rizičnih čimbenika za aterotrombozu: dob ≥65 godina, diabetes mellitus kojeg je potrebno liječiti, drugi prethodni IM, dokaz bolesti koronarnih arterija koja zahvaća višestruke krvne žile ili kronično oštećenje funkcije bubrega koje nije u završnom stadiju.
English: The use of ticagrelor in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events (see sections 4.8 and 5.1).
Croatian: Primjenu tikagrelora kod bolesnika s poznatim povećanim rizikom od krvarenja treba procijeniti u odnosu na korist u smislu prevencije aterotrombotskih događaja (vidjeti dijelove 4.8 i 5.1).
English: 10 x 1 orodispersible tablets 56 x 1 orodispersible tablets 60 x 1 orodispersible tablets
Croatian: 10x1 raspadljiva tableta za usta 56x1 raspadljiva tableta za usta 60x1 raspadljiva tableta za usta
English: Ticagrelor is a mild CYP3A4 inhibitor.
Croatian: Tikagrelor je blagi inhibitor CYP3A4.
English: In patients with end stage renal disease on haemodialysis AUC and Cmax of ticagrelor 90 mg administered on a day without dialysis were 38% and 51% higher compared to subjects with normal renal function.
Croatian: U bolesnika u završnom stadiju bubrežne bolesti na hemodijalizi, AUC i Cmax tikagrelora u dozi od 90 mg primijenjenog u danu bez dijalize bili su 38% i 51% viši u usporedbi sa ispitanicima sa normalnom funkcijom bubrega.
English: • PVC-PVDC/Al transparent calendar blister (with sun/moon symbols) of 14 tablets; cartons of 14 tablets (1 blister), 56 tablets (4 blisters) and 168 tablets (12 blisters).
Croatian: • PVC-PVDC/Al prozirni kalendarski blister (sa simbolima sunca i mjeseca) sa 14 tableta; kutije sa 14 tableta (1 blister), 56 tableta (4 blistera) i 168 tableta (12 blistera).
English: Adverse reactions are listed by MedDRA System Organ Class (SOC).
Croatian: Nuspojave su navedene prema MedDRA-inoj klasifikaciji organskih sustava (SOC, engl.
English: The increase in ventricular pauses in the acute phase of ACS was more pronounced in ticagrelor patients with history of CHF (9.2% versus 5.4% in patients without CHF history; for clopidogrel patients, 4.0% in those with versus 3.6% in those without CHF history).
Croatian: Povećanje u ventrikularnim stankama u akutnoj fazi akutnog koronarnog sindroma bilo je izraženije kod bolesnika koji su primali tikagrelor s kroničnim zatajivanjem srca (KZS) u anamnezi (9,2% u odnosu na 5,4% kod bolesnika bez anamneze KZS; za ispitanike s klopidogrelom 4,0% u onih koji su imali anamnezu KZS u odnosu na 3,6% onih koji je nisu imali).
English: • Bleeding from your stomach lining (ulcer)
Croatian: • Krvarenje iz sluznice želuca (čira)
English: The inhibition of platelet aggregation (IPA) effect of ticagrelor was independent of dialysis in patients with end stage renal disease and similar to subjects with normal renal function (see section 4.2).
Croatian: Učinak tikagrelora na inhibiciju agregacije trombocita (engl. inhibition of platelet aggregation, IPA) bio je neovisan o dijalizi u bolesnika u završnom stadiju bubrežne bolesti i sličan kao u ispitanika sa normalnom funkcijom bubrega (vidjeti dio 4.2).
English: Eye haemorrhage
Croatian: Poremećaji oka
English: The corresponding numbers in PEGASUS were 9.1%, 8.8% and 5.5% for ticagrelor 90 mg, 60 mg and placebo, respectively.
Croatian: Odgovarajuće vrijednosti u studiji PEGASUS bile su 9,1%, 8,8% odnosno 5,5% za tikagrelor u dozi od 90 mg ili 60 mg, odnosno za placebo.
English: Post procedural haemorrhage, Traumatic bleedings e.g. bleeding from bladder cancer, gastric cancer, colon cancer e.g. increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis Identified in post-marketing experience Frequencies derived from lab observations (Uric acid increases to >upper limit of normal from baseline below or within reference range.
Croatian: Krvarenje nakon zahvata, traumatsko krvarenje npr. krvarenje raka mokraćnog mjehura, raka želuca ili raka debelog crijeva npr. povećana sklonost stvaranju modrica, spontanom hematomu, hemoragijskoj dijatezi Identificirano nakon stavljanja lijeka u promet Učestalosti dobivene iz laboratorijskih pretraga (razina uratne kiseline se povećava do >gornje granice normale u odnosu na početnu vrijednost koja je ispod ili unutar referentnog raspona.
English: • perforated unit dose blisters in cartons of 10 x 1, 56 x 1 and 60 x 1 orodispersible tablets.
Croatian: • perforiranim blisterima s jediničnim dozama u kutiji sa 10x1, 56x1 i 60x1 raspadljivom tabletom za usta.
English: Ticagrelor 90 mg twice daily (% patients with event) N=9333
Croatian: Tikagrelor 90 mg dvaput dnevno (% bolesnika s događajem) N=9333
English: Hyperuricaemia may occur during treatment with ticagrelor (see section 4.8).
Croatian: Pri liječenju tikagrelorom može doći do hiperuricemije (vidjeti dio 4.8.).
English: • You have had a blood test that showed more than the usual amount of uric acid.
Croatian: • Ako ste na krvnim pretragama imali vrijednosti mokraćne kiseline više od uobičajenih.
English: The steady state volume of distribution of ticagrelor is 87.5 l. Ticagrelor and the active metabolite is extensively bound to human plasma protein (>99.0%).
Croatian: Tikagrelor i aktivni metabolit se opsežno vežu za proteine ljudske plazme (> 99,0%).
English: Spontaneous ICHs were reported in similar rates for ticagrelor 60 mg and ASA therapy alone (n=13, 0.2% in both treatment groups).
Croatian: Spontana intrakranijalna krvarenja prijavljena su sa sličnim stopama za tikagrelor od 60 mg i terapiju samo acetilsalicilatnom kiselinom (n = 13, 0,2% u obje terapijske skupine).
English: There was no effect of ticagrelor on diltiazem plasma levels.
Croatian: Nisu zabilježeni učinci tikagrelora na plazmatske razine diltiazema.
English: • calendar blisters (with sun/moon symbols) in cartons of 14, 56 and 168 tablets
Croatian: • kalendarskim blisterima (sa simbolima sunca i mjeseca) u kutijama sa 14, 56 i 168 tableta
English: In rabbits a slight delay in hepatic maturity and skeletal development was seen in foetuses from dams at high dose without showing maternal toxicity (safety margin of 4.5).
Croatian: Kod zečeva je uočeno manje kašnjenje u sazrijevanju jetre i razvoju kostiju kod fetusa ženki tretiranih visokim dozama kod kojih nije uočena toksičnost za majku (granica sigurnosti primjene od 4,5).
English: 14 film-coated tablets 56 film-coated tablets 60 film-coated tablets 100x1 film-coated tablets 168 film-coated tablets 180 film-coated tablets
Croatian: 14 filmom obloženih tableta 56 filmom obloženih tableta 60 filmom obloženih tableta 100x1 filmom obložena tableta 168 filmom obloženih tableta 180 filmom obloženih tableta
English: Bleeding findings in PLATO
Croatian: Zaključci o krvarenju iz studije PLATO
English: Treatment with Brilique 90 mg twice daily is recommended for 12 months in ACS patients unless discontinuation is clinically indicated (see section 5.1).
Croatian: Preporučeno trajanje liječenja lijekom Brilique 90 mg je 12 mjeseci u bolesnika s akutnim koronarnim sindromom, osim ako je prestanak uzimanja klinički indiciran (vidjeti dio 5.1).
English: Thus, Brilique 90 mg twice daily together with low-dose ASA can be used in patients with ACS (unstable angina, non-ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Croatian: Prema tome, Brilique od 90 mg dvaput dnevno primijenjen zajedno s niskom dozom acetilsalicilatne kiseline može se primjenjivati u bolesnika s akutnim koronarnim sindromom (nestabilna angina, infarkt miokarda bez ST elevacije [NSTEMI] ili infarkt miokarda sa ST elevacijom [STEMI]); uključujući bolesnike koji su liječeni lijekovima kao i one koji su liječeni perkutanom koronarnom intervencijom (PCI) ili aortokoronarnom premosnicom (CABG).
English: In PLATO, patients on ticagrelor had a higher incidence of discontinuation due to adverse events than clopidogrel (7.4% vs. 5.4%).
Croatian: U studiji PLATO, incidencija prekida liječenja zbog nuspojava bila je viša u bolesnika koji su primali tikagrelor nego u onih koji su primali klopidogrel (7,4% naprema 5,4%).
English: Subcutaneous or dermal bleeding h, Rash,
Croatian: Potkožno ili kožno krvarenje h, osip,
English: Figure 1 - Analysis of primary clinical composite endpoint of CV death, MI and stroke (PLATO)
Croatian: Slika 1 - Analiza primarnog kliničkog kompozitnog ishoda KV smrti, infarkta miokarda i moždanog udara (PLATO)
English: The AUC of the active metabolite was increased by 32% and Cmax was decreased by 15% in the presence of cyclosporine.
Croatian: Prisutnost ciklosporina povećala je AUC aktivnog metabolita za 32% i smanjila njegov Cmax za 15%.
English: There was no effect of simvastatin on ticagrelor plasma levels.
Croatian: Nije bilo učinka simvastatina na plazmatsku razinu tikagrelora.
English: • Strong CYP3A4 inhibitors - Co-administration of ketoconazole with ticagrelor increased the ticagrelor Cmax and AUC equal to 2.4-fold and 7.3-fold, respectively.
Croatian: • Jaki inhibitori CYP3A4 - istodobna primjena ketokonazola s tikagrelorom je povećala Cmax i AUC tikagrelora za 2,4 puta, odnosno 7,3 puta.
English: Figure 2 - Analysis of primary clinical composite endpoint of CV death, MI and stroke (PEGASUS)
Croatian: Slika 2 - Analiza primarnog kliničkog kompozitnog ishoda KV smrti, IM i moždanog udara (PEGASUS)
English: The pharmacokinetics of ticagrelor and AR-C124910XX in patients with a history of MI were generally similar to that in the ACS population.
Croatian: Farmakokinetika tikagrelora i AR-C124910XX u bolesnika s infarktom miokarda u anamnezi bila je uglavnom slična onoj u populaciji bolesnika s akutnim koronarnim sindromom.
English: The corresponding numbers for gout/gouty arthritis in PEGASUS were 1.6%, 1.5% and 1.1% for ticagrelor 90 mg, 60 mg and placebo, respectively.
Croatian: Odgovarajuće vrijednosti za giht/urični artritis u studiji PEGASUS bile su 1,6%, 1,5% i 1,1% za tikagrelor od 90 mg ili 60 mg, odnosno za placebo.
English: Discontinuation of treatment due to bleeding was more common with ticagrelor 60 mg compared to ASA therapy alone (6.2% and 1.5%, respectively).
Croatian: Prekid liječenja zbog krvarenja bio je češći za tikagrelor od 60 mg, u usporedbi s terapijom samo acetilsalicilatnom kiselinom (6,2% odnosno 1,5%).
English: As a precautionary measure, the use of ticagrelor in patients with uric acid nephropathy is discouraged.
Croatian: Kao mjera predostrožnosti, uporaba tikagrelora se ne preporučuje kod bolesnika s nefropatijom uzrokovanom povećanom koncentracijom uratne kiseline.
English: Ticagrelor has been documented to augment the following adenosine-induced effects in healthy subjects and in patients with ACS: vasodilation (measured by coronary blood flow increases in healthy volunteers and ACS patients; headache), inhibition of platelet function (in human whole blood in vitro) and dyspnoea.
Croatian: Zabilježeno je da tikagrelor, kod zdravih ispitanika i kod bolesnika s akutnim koronarnim sindromom, pospješuje sljedeće adenozinom inducirane učinke: vazodilataciju (mjereno kao povećanje koronarnog protoka krvi kod zdravih ispitanika i kod bolesnika s akutnim koronarnim sindromom; glavobolja), inhibiciju funkcije trombocita (mjereno in vitro u ljudskoj punoj krvi) i dispneju.
English: Major Fatal/Life-threatening Bleed: Clinically apparent with >50 g/L decrease in haemoglobin or ≥4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolaemic shock or severe hypotension requiring pressors or surgery.
Croatian: Velika fatalna / krvarenja opasna po život: Klinički vidljiva, sa smanjenjem hemoglobina >50 g/l ili transfuzijom ≥4 jedinice eritrocita; ili je fatalno; ili je intrakranijalno; ili je intraperikardijalno sa srčanom tamponadom; ili s hipovolemijskim šokom ili teškom hipotenzijom koja zahtijeva lijekove za povišenje krvnog tlaka ili operaciju.
English: • PVC-PVDC/Al perforated unit dose transparent blister of 10 tablets; cartons of 100x1 tablets (10 blisters).
Croatian: • PVC-PVDC/Al perforirani prozirni blisteri s jediničnim dozama s 10 tableta; kutije sa 100x1 tabletom (10 blistera).
English: The following adverse reactions have been identified following studies or have been reported in post-marketing experience with ticagrelor (Table 1).
Croatian: Nakon provedenih studija, te nakon stavljanja tikagrelora u promet uočene su sljedeće nuspojave (Tablica 1).
English: • To make sure there is no medicine left, rinse the empty glass with another half a glass of water and drink it.
Croatian: • Kako biste bili sigurni da nema zaostalog lijeka, isperite praznu čašu sa još pola čaše vode i to popijte Ako ste u bolnici, ovu tabletu možete dobiti pomješanu s malo vode putem cijevi kroz nos (nazogastrična cijev).
English: • You are taking any of the following medicines: - ketoconazole (used to treat fungal infections) - clarithromycin (used to treat bacterial infections) - nefazodone (an antidepressant) - ritonavir and atazanavir (used to treat HIV infection and AIDS) Do not take Brilique if any of the above applies to you.
Croatian: • ako uzimate bilo koji od ovih lijekova: - ketokonazol (za liječenje gljivičnih infekcija), - klaritromicin (za liječenje bakterijskih infekcija), - nefazodon (antidepresiv), - ritonavir i atazanavir (za liječenje infekcije HIV-om i SIDA-e).
English: There is limited experience with ticagrelor in patients with moderate hepatic impairment, therefore, caution is advised in these patients (see sections 4.2 and 5.2).
Croatian: Iskustvo s tikagrelorom u bolesnika s umjerenim oštećenjem funkcije jetre je ograničeno, stoga se preporučuje oprez u ovih bolesnika (vidjeti dijelove 4.2 i 5.2).
English: Ticagrelor 90 mg twice daily N=9235
Croatian: Tikagrelor 90 mg dvaput dnevno N=9235
English: In PEGASUS, patients with history of MI with prior ischaemic stroke were not included.
Croatian: U studiju PEGASUS nisu bili uključeni bolesnici s infarktom miokarda u anamnezi i prethodnim ishemijskim moždanim udarom.
English: Based on a population pharmacokinetic analysis of the PEGASUS study the median ticagrelor Cmax was 391 ng/ml and AUC was 3801 ng*h/ml at steady state for ticagrelor 60 mg. For ticagrelor 90 mg Cmax was 627 ng/ml and AUC was 6255 ng*h/ml at steady state.
Croatian: Temeljeno na analizi populacijske farmakokinetike u studiji PEGASUS, medijan tikagrelora Cmax bio je 391 ng/ml, a AUC 3801 ng*h/ml u stanju ravnoteže za tikagrelor od 60 mg.
English: Major Other: Clinically apparent with 30-50 g/L decrease in haemoglobin or 2-3 red cell units transfused; or significantly disabling.
Croatian: Ostala velika: Klinički vidljiva, sa smanjenjem hemoglobina od 30-50 g/l ili transfuzijom 2-3 jedinice eritrocita; ili značajno onesposobljenje osobe.
English: EU/1/10/655/012 10 x 1 orodispersible tablets EU/1/10/655/013 56 x 1 orodispersible tablets EU/1/10/655/014 60 x 1 orodispersible tablets
Croatian: EU/1/10/655/012 10x1 raspadljiva tableta za usta EU/1/10/655/013 56x1 raspadljiva tableta za usta EU/1/10/655/014 60x1 raspadljiva tableta za usta
English: In PEGASUS, patients on ticagrelor had a higher incidence of discontinuation due to adverse events compared to ASA therapy alone (16.1% for ticagrelor 60 mg with ASA vs. 8.5% for ASA therapy alone).
Croatian: U studiji PEGASUS, incidencija prekida liječenja zbog nuspojava bila je viša u bolesnika koji su primali tikagrelor nego u onih koji su primali samo acetilsalicilatnu kiselinu (16,1% za tikagrelor od 60 mg u kombinaciji s acetilsalicilatnom kiselinom naprema 8,5% za terapiju samo acetilsalicilatnom kiselinom).
English: No dose adjustment is needed for patients with mild hepatic impairment.
Croatian: Nije potrebna prilagodba doze u bolesnika s blagim oštećenjem funkcije jetre.
English: • PVC-PVDC/Al transparent blister (with sun/moon symbols) of 10 tablets; cartons of 60 tablets (6 blisters) and 180 tablets (18 blisters).
Croatian: • PVC-PVDC/Al prozirni blister (sa simbolima sunca i mjeseca) s 10 tableta; kutije sa 60 tableta (6 blistera) i 180 tableta (18 blistera).
English: PLATO Major Fatal/life-threatening: Fatal bleeding, OR any intracranial bleeding, OR intrapericardial with cardiac tamponade, OR with hypovolaemic shock or severe hypotension requiring pressors/inotropes or surgery OR clinically apparent with >50 g/L decrease in haemoglobin or ≥4 red cell units transfused.
Croatian: PLATO Velika Fatalna/opasna po život: Fatalna krvarenja, ILI bilo koje intrakranijalno krvarenje, ILI intraperikardijalno krvarenje sa srčanom tamponadom, ILI sa hipovlemijskim šokom ili teškom hipotenzijom koja zahtijeva lijekove za povišenje krvnog tlaka ili operaciju, ILI klinički vidljivo sa smanjenjem hemoglobina od >50 g/l ili transfuzijom ≥4 jedinice eritrocita
English: EU/1/10/655/007 14 film-coated tablets EU/1/10/655/008 56 film-coated tablets EU/1/10/655/009 60 film-coated tablets EU/1/10/655/010 168 film-coated tablets EU/1/10/655/011 180 film-coated tablets
Croatian: EU/1/10/655/007 14 filmom obloženih tableta EU/1/10/655/008 56 filmom obloženih tableta EU/1/10/655/009 60 filmom obloženih tableta EU/1/10/655/010 168 filmom obloženih tableta EU/1/10/655/011 180 filmom obloženih tableta
English: ASA alone N=6996
Croatian: Samo acetilsalicilatna kiselina N = 6996
English: Brilique contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially ‘sodium-free'.
Croatian: Brilique sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
English: No dose adjustment is required in elderly (see section 5.2).
Croatian: Nije potrebna prilagodba doze kod starijih osoba (vidjeti dio 5.2).
English: • Non-Steroidal Anti-Inflammatory Drugs (abbreviated as NSAIDs) often taken as painkillers such as ibuprofen and naproxen.
Croatian: • nesteroidni protuupalni lijekovi (skraćeno NSAIL) kao što su lijekovi protiv bolova poput ibuprofena i naproksena.
English: Uric acid increase
Croatian: Povećanje razine uratne (mokraćne) kiseline
English: How to store Brilique
Croatian: Kako čuvati Brilique
English: EU/1/10/655/001 60 film-coated tablets EU/1/10/655/002 180 film-coated tablets EU/1/10/655/003 14 film-coated tablets EU/1/10/655/004 56 film-coated tablets EU/1/10/655/005 168 film-coated tablets EU/1/10/655/006 100x1 film-coated tablets
Croatian: EU/1/10/655/001 60 filmom obloženih tableta EU/1/10/655/002 180 filmom obloženih tableta EU/1/10/655/003 14 filmom obloženih tableta EU/1/10/655/004 56 filmom obloženih tableta EU/1/10/655/005 168 filmom obloženih tableta EU/1/10/655/006 100x1 filmom obloženih tableta
English: False negative results in a platelet function test (to include, but may not be limited to the HIPA test) for HIT have been reported in patients administered ticagrelor.
Croatian: Kod bolesnika koji su primali tikagrelor prijavljeni su lažno negativni rezultati testa za određivanje funkcije trombocita (što uključuje, ali ne mora biti ograničeno samo na test HIPA) koji se koristi za dijagnosticiranje HIT-a.
English: Women should use appropriate contraceptive measures to avoid pregnancy while taking this medicine.
Croatian: Tijekom uzimanja ovog lijeka, žene trebaju koristiti odgovarajuću kontracepcijsku zaštitu kako bi izbjegle trudnoću.
English: • The other ingredients are: mannitol (E421), microcrystalline cellulose (E460), crospovidone (E1202), xylitol (E967), anhydrous calcium hydrogen phosphate (E341), sodium stearyl fumarate, hydroxypropylcellulose (E463), colloidal anhydrous silica.
Croatian: • Drugi sastojci su: manitol (E421), mikrokristalična celuloza (E460), krospovidon (E1202), ksilitol (E967), bezvodni kalcijev hidrogenfosfat (E341), natrijev stearilfumarat, hidroksipropilceluloza (E463), koloidni, bezvodni silicijev dioksid.
English: It reduces the chances of you having another heart attack, stroke or dying from a disease related to your heart or blood vessels.
Croatian: Brilique smanjuje vjerojatnost drugog srčanog, moždanog udara ili smrti uslijed bolesti povezane s Vašim srcem ili krvnim žilama.
English: Use of ticagrelor is contraindicated in patients with severe hepatic impairment (see sections 4.2 and 4.3).
Croatian: Primjena tikagrelora kontraindicirana je u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.2 i 4.3).
English: ACS patients with prior ischaemic stroke can be treated with ticagrelor for up to 12 months (PLATO study).
Croatian: Bolesnici s prethodnim ishemijskim moždanim udarom Bolesnici s akutnim koronarnim sindromom koji su prethodno imali ishemijski moždani udar mogu biti liječeni tikagrelorom tijekom najdulje 12 mjeseci (studija PLATO).
English: Ticagrelor and clopidogrel did not differ in non-CABG PLATO-defined Major Fatal/Lifethreatening bleeding, but PLATO-defined Total Major, TIMI Major, and TIMI Major + Minor bleeding were more common with ticagrelor.
Croatian: Krvarenje koje nije povezano s CABG i krvarenje koje nije povezano s procedurama: Tikagrelor i klopidogrel se nisu razlikovali u pogledu ne-CABG PLATO-definiranih velikih fatalnih/opasnih po život krvarenja, ali su PLATO-definirana ukupna velika, TIMI velika i TIMI velika + manja krvarenja bila češća s tikagrelorom.
English: PLATO Major Other: Significantly disabling, OR clinically apparent with 30-50 g/L decrease in haemoglobin, OR 2-3 red cell units transfused.
Croatian: Ostala PLATO velika: Značajno onesposobljenje osobe, ILI klinički vidljiva sa smanjenjem hemoglobina od 30-50 g/l, ILI transfuzijom 2-3 jedinice eritrocita.
English: Dyspnoea was reported in patients treated with ticagrelor.
Croatian: Dispneja je prijavljena u ispitanika koji su primali tikagrelor.
English: The PLATO study included 18,624 patients who presented within 24 hours of onset of symptoms of unstable angina (UA), non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI), and were initially managed medically, or with percutaneous coronary intervention (PCI), or with CABG.
Croatian: U studiju PLATO uključeno je 18 624 bolesnika u roku od 24 sata od pojave simptoma nestabilne angine, infarkta miokarda bez ST elevacije (NSTEMI) ili infarkta miokarda sa ST elevacijom (STEMI), te su inicijalno bili zbrinuti medikamentozno, ili liječeni perkutanom koronarnom intervencijom (PCI), ili CABG-om.
English: The PLATO study included 18,624 patients who presented within 24 hours of onset of symptoms of unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI), and were initially managed medically, or with percutaneous coronary intervention (PCI), or with CABG.
Croatian: U studiju PLATO uključeno je 18 624 bolesnika u roku od 24 sata od pojave simptoma nestabilne angine, infarkta miokrada bez ST elevacije (NSTEMI) ili infarkta miokarda sa ST elevacijom (STEMI), te su inicijalno bili zbrinuti medikamentozno, ili liječeni perkutanom koronarnom intervencijom (PCI), ili CABG-om.
English: Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4.
Croatian: Tikagrelor je primarno supstrat i blagi inhibitor CYP3A4.
English: Co-administration of cyclosporine (600 mg) with ticagrelor increased ticagrelor Cmax and AUC equal to 2.3-fold and 2.8-fold, respectively.
Croatian: Istodobna primjena ciklosporina (600 mg) s tikagrelorom povećala je Cmax tikagrelora 2,3 puta, a njegov AUC 2,8 puta.
English: Diarrhoea, Nausea, Dyspepsia, Constipation
Croatian: Krvarenja u probavnom sustavu g, proljev, mučnina, dispepsija, konstipacija
English: Fatal
Croatian: Fatalna
English: Tablet film-coating: hypromellose (E464), titanium dioxide (E171), talc, macrogol 400, iron oxide yellow (E172).
Croatian: Film ovojnica tablete: hipromeloza (E464), titanijev dioksid (E171), talk, makrogol 400, žuti željezov oksid (E172).